Supraciliary Micro-Stent Implantation in Combination With Phacoemulsification: 2-Year Single-Center Experience in Warsaw, Poland

Sunday, April 19, 2015: 1:41 PM
Room 1A (San Diego Convention Center)
Marek Rękas, MD

To evaluate the 2-year safety and clinical outcomes of the CyPass Micro-Stent, an ab interno supraciliary implant, in patients with open-angle glaucoma undergoing cataract surgery.

Eyes (n=23) were enrolled in a single site at the Military Institute of Medicine in Warsaw, Poland. In each subject, the supraciliary device was implanted following cataract surgery through the same corneal incision. Medications were stopped following the procedure and re-introduced as deemed necessary by the investigator, per each subject’s intraocular pressure (IOP) target. Main outcomes were adverse events, IOP changes, and number of IOP-lowering medications at 2 years.

At baseline, (n=23) subjects had a mean IOP of 16.9 ± 5.0 mmHg on a mean of 2.3 ± 0.9 IOP-lowering medications, and 78% of patients were taking 2 or more medications. The device was successfully implanted in all 23 eyes with no major intraoperative complications. During the two-year follow-up, there were no major sight-threatening adverse events related to device implantation. At 1 year (n=19) and 2 years (n=18), mean IOP was reduced to 14.2 ± 3.0 mmHg and 15.1 ± 1.8 mmHg respectively. Mean medication usage reduced to 0.3 ± 0.7 at the end of 2 years, and 78% of subjects were on no medications.

CyPass Micro-Stent implantation in combination with cataract surgery is a minimally invasive procedure with an excellent safety profile and can reduce IOP and IOP-lowering medication usage at 2 years postoperatively. For many glaucoma patients, the CyPass Micro-Stent may eliminate the need for medications altogether.